Schlogl H, Kabisch S, Horstmann A, Lohmann G, Muller K, Lepsien J, et al
Ethics declarations Competing interests We disclose the following potential conflicts of interest regarding the publication of this manuscript: This research was partly funded by Cleara Biotech
Do not use retatrutide if you have: Personal or family history of medullary thyroid carcinoma Multiple Endocrine Neoplasia syndrome type 2 History of pancreatitis Severe gastroparesis or other serious GI motility disorders Known hypersensitivity to any component of the drug Use with caution and close monitoring if you have: Existing cardiovascular disease, given the heart rate increase Gallbladder disease or a history of gallstones Kidney disease, as dehydration from GI side effects can worsen kidney function Type 1 diabetes or insulin-dependent Type 2 diabetes A history of eating disorders, as extreme appetite suppression can interact with disordered eating patterns in unpredictable ways Pregnancy is an absolute contraindication
Neural stem cells and the developing brain When we examined the effect of TMLHE mutations in mice, we found these mutations specifically affect neural stem cells during early stages of brain development
My bottom line: a balanced view Thoughtful use, open communication and routine monitoring keep B12 injections useful and safe
#GLP1 #Inflammation #Metabolism #Biotech #HealthcareInnovation #DrugMechanism #ChronicDisease GLP-1s & Bone Loss Recent data from early 2026 suggests that while GLP-1 receptor agonists (like semaglutide and tirzepatide) are revolutionary for weight management, they do present a real "skeletal cost" that requires proactive management